NewEdge Advisors
ALNY icon

NewEdge Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

NewEdge Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$811K Buy
3,287
+717
+28% +$182K ﹤0.01% 1854
2026
Q2 		$774K Buy
2,570
+254
+11% +$76.6K ﹤0.01% 1835
2026
Q1 		$766K Sell
2,316
-701
-23% -$239K ﹤0.01% 1667
2025
Q4 		$1.2M Buy
3,017
+1,493
+98% +$661K ﹤0.01% 1376
2025
Q3 		$695K Buy
1,524
+820
+116% +$334K ﹤0.01% 1619
2025
Q2 		$229K Buy
704
+703
+70,300% +$195K ﹤0.01% 2153
2025
Q1 		$270 Sell
1
-972
-100% -$250K ﹤0.01% 3778
2024
Q4 		$229K Buy
973
+972
+97,200% +$256K ﹤0.01% 2021
2024
Q3 		$275 Sell
1
-994
-100% -$259K ﹤0.01% 3662
2024
Q2 		$242K Buy
995
+977
+5,428% +$154K ﹤0.01% 1828
2024
Q1 		$2.69K Buy
18
+14
+350% +$2.34K ﹤0.01% 3314
2023
Q4 		$765 Hold
4
– – ﹤0.01% 3497
2023
Q3 		$708 Hold
4
– – ﹤0.01% 3215
2023
Q2 		$760 Hold
4
– – ﹤0.01% 3281
2023
Q1 		$801 Sell
4
-60
-94% -$12.6K ﹤0.01% 3187
2022
Q4 		$13.8K Buy
+64
New +$13.7K ﹤0.01% 2263

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

NewEdge Advisors's ALNY Position: Q3 2026 in Review

NewEdge Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 28% in Q3 2026, buying an estimated $182K and bringing the position to 3,287 shares worth $811K. The position accounts for ﹤0.01% of the portfolio, ranked #1854.

NewEdge Advisors first reported a position in ALNY in Q4 2022 and has held it in 16 quarters since. The position peaked at $1.2M in Q4 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • NewEdge Advisors held 3,287 shares of Alnylam Pharmaceuticals worth $811K as of Q3 2026.
  • NewEdge Advisors bought 717 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $182K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q3 2026, its #1854 holding.
  • NewEdge Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
  • NewEdge Advisors's Alnylam Pharmaceuticals position peaked at $1.2M in Q4 2025.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.